Recently, attention has been focused on pharmacological treatments that increase
HDL cholesterol to prevent
coronary artery disease. Despite three decades of extensive research of human
apolipoprotein A-I (
apoA-I), the major
protein component of HDL, the molecular basis for its antiatherogenic and anti-inflammatory functions remain elusive. Another
protein component of HDL,
apoA-II, has structural features similar to those of
apoA-I but does not possess atheroprotective properties. To understand the molecular basis for the effectiveness of
apoA-I, we used model synthetic
peptides. We designed analogs of the class A amphipathic helical motif in
apoA-I that is responsible for solubilizing
phospholipids. None of these analogs has sequence homology to
apoA-I, but all are similar in their
lipid-associating structural motifs. Although all of these
peptide analogs interact with
phospholipids to form
peptide:
lipid complexes, the biological properties of these analogs are different. Physical-chemical and NMR studies of these
peptides have enabled the delineation of structural requirements for atheroprotective and anti-inflammatory properties in these
peptides. It has been shown that
peptides that interact strongly with
lipid acyl chains do not have antiatherogenic and anti-inflammatory properties. In contrast,
peptides that associate close to the
lipid head group (and hence do not interact strongly with the
lipid acyl chain) are antiatherogenic and anti-inflammatory. Understanding the structure and function of
apoA-I and HDL through studies of the amphipathic helix motif may lead to
peptide-based
therapies for inhibiting
atherosclerosis and other related inflammatory
lipid disorders.